Though winter storm Pax put the freeze on air and ground traffic in the Northeast U.S. after ravaging the South, biotech funders seemed to feel little of the chill, with PTC Therapeutics Inc. and Macrogenics Inc. pricing public offerings for $109.7 million and $109.5 million, respectively.